KYMR Kymera Therapeutics, Inc. - Common Stock
$124.35
价格 · 八月 20, 2026
截至...的财报数据 八月 5, 2026
52周区间
$40–$130
94% of range
分析师评级
BUY
30 analysts
目标价
$131
+5% upside
P/E (TTM)
-33.7
ROE
-24.4%
净利润率
-794.0%
关于 Kymera Therapeutics, Inc. - Common Stock 公司概况（来自维基百科）
KYMR 股票快照 价格、市值、P/E、EPS、ROE、负债/权益、52周范围
价格
$124.35
市值
$10.11B
P/E (TTM)
-33.7
每股收益 (TTM)
$-3.69
营收 (TTM)
$39M
股息收益率
—
ROE
-24.4%
负债/权益
—
52周区间
$40 – $130
KYMR 股价图表 包含技术指标的日 OHLCV — 平移、缩放和自定义您的视图
Configure
10年表现 收入、净利润、利润率和每股收益趋势
营收与净利润
$39M
2019-12-31
→
2025-12-31
EPS
$-3.69
2020-12-31
→
2025-12-31
自由现金流
$-234M
2020-12-31
→
2025-12-31
利润率
-794.0%
估值 P/E、P/S、P/B、EV/EBITDA 比率 — 该股票是昂贵还是便宜？
指标
5年趋势
KYMR
同行中位数
P/E (TTM)
-33.7
16.0
P/S (TTM) (市销率 (TTM))
257.9
32.5
P/B (市净率)
6.4
3.9
Price / FCF (股价/自由现金流)
-43.2
—
盈利能力 毛利率、营业利润率和净利率；股本回报率 (ROE)、资产回报率 (ROA)、投入资本回报率 (ROIC)
指标
5年趋势
KYMR
同行中位数
Operating Margin (营业利润率)
-891.1%
—
Net Profit Margin (净利润率)
-794.0%
-93.3%
ROA
-22.9%
-22.2%
ROE
-24.4%
-37.6%
ROIC
-22.1%
—
财务健康 债务、流动性、偿付能力 — 资产负债表强度
指标
5年趋势
KYMR
同行中位数
Current Ratio (流动比率)
10.5
5.7
Quick Ratio (速动比率)
4.3
—
成长 营收、每股收益 (EPS) 和净利润增长：同比、3年复合年增长率 (CAGR)、5年复合年增长率 (CAGR)
指标
5年趋势
KYMR
同行中位数
Revenue YoY (营收同比增长)
-16.7%
—
Revenue CAGR 3Y (营收3年复合年增长率)
-5.7%
—
Revenue CAGR 5Y (营收5年复合年增长率)
2.9%
—
资本效率 资产周转率、库存周转率、应收账款周转率
指标
5年趋势
KYMR
同行中位数
KYMR 分析师共识 看涨和看跌分析师观点、12个月价格目标、上涨空间
买入
30 位分析师
- 强烈买入 10 33.3%
- 买入 16 53.3%
- 持有 4 13.3%
- 卖出 0 0.0%
- 强烈卖出 0 0.0%
12个月价格目标
22 位分析师 · 2026-08-16
中位数
$133.00
现在
$124.35
最低
$111.00
最高
$155.00
中位数目标
$133.00
+7.0%
平均目标
$130.91
+5.3%
收益历史 每股收益实际值 vs 预估值，惊喜%，达标率，下次财报日期
平均惊喜
0.00%
| 期间 | EPS Actual | EPS 预期 | 惊喜 |
|---|---|---|---|
| 2026年6月30日 | $-0.62 | $-0.73 | 0.11% |
| 2026年3月31日 | $-0.71 | $-0.90 | 0.19% |
| 2025年12月31日 | $-0.97 | $-0.81 | -0.16% |
| 2025年9月30日 | $-0.94 | $-0.82 | -0.12% |
| 2025年6月30日 | $-0.95 | $-0.83 | -0.12% |
| 2025年3月31日 | $-0.82 | $-0.93 | 0.11% |
同行比较（GICS 子行业） 关键指标与行业同行对比
| 股票代码 | 市值 | P/E | 营收同比增长 | 净利润率 | ROE | 毛利率 |
|---|---|---|---|---|---|---|
| KYMR | $6.33B | -21.1 | -16.7% | -794.0% | -24.4% | — |
| HALO | $7.93B | 26.3 | 37.5% | 22.7% | 166.1% | — |
| CYTK | $7.81B | -9.7 | 376.6% | -891.6% | 152.7% | — |
| PRAX | $7.43B | -21.9 | 249.5% | — | -47.3% | — |
| APGE | $5.16B | -17.9 | — | — | — | — |
| KRYS | $7.20B | 36.0 | 33.9% | 52.6% | 18.1% | — |
| SMMT | $13.56B | -12.1 | — | — | -235.1% | — |
| IONS | $12.92B | -33.2 | — | — | -68.1% | — |
| PTGX | $5.47B | -42.6 | -89.4% | -282.8% | -20.3% | — |
| SYRE | $2.56B | 10.1 | -62.0% | — | -26.5% | — |
完整基本面 所有年度指标 — 损益表、资产负债表、现金流量表
损益表 15
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $39M | $47M | $79M | $47M | $73M | $34M | $3M | |
| Cost of Revenue | $39M | $47M | $79M | $47M | · | · | · | |
| R&D Expense | $317M | $240M | $189M | $164M | $137M | $62M | $37M | |
| SG&A Expense | $68M | $64M | $55M | $44M | $36M | $18M | $8M | |
| Operating Expenses | $389M | $309M | $244M | $208M | $173M | $80M | $45M | |
| Operating Income | $-349M | $-262M | $-166M | $-161M | $-101M | $-46M | $-42M | |
| Other Non-op | $38M | $38M | $19M | $6M | $313.0K | $711.0K | $959.0K | |
| Pretax Income | $-311M | · | · | · | · | · | · | |
| Income Tax | $0 | · | · | $0 | $0 | $0 | $0 | |
| Net Income | $-311M | $-224M | $-147M | $-155M | $-100M | $-46M | $-41M | |
| EPS (Basic) | $-3.69 | $-2.98 | $-2.52 | $-2.87 | $-2.09 | $-3.15 | · | |
| EPS (Diluted) | $-3.69 | $-2.98 | $-2.52 | $-2.87 | $-2.09 | $-3.15 | · | |
| Shares (Basic) | 84,490,585 | 75,043,991 | 58,365,499 | 53,933,229 | 47,989,023 | 17,349,582 | · | |
| Shares (Diluted) | 84,490,585 | 75,043,991 | 58,365,499 | 53,933,229 | 47,989,023 | 17,349,582 | · | |
| EBITDA | $-341M | $-254M | $-162M | $-158M | $-98M | $-45M | · |
资产负债表 21
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $357M | $120M | $110M | $68M | $48M | $31M | $76M | |
| Receivables | $0 | $0 | $15M | $0 | · | · | · | |
| Prepaid Expense | $23M | $22M | $12M | $10M | $9M | $5M | $888.0K | |
| Current Assets | $871M | $510M | $405M | $419M | $451M | $302M | $93M | |
| PP&E (Net) | $43M | $50M | $48M | $13M | $12M | $11M | $4M | |
| PP&E (Gross) | $65M | $67M | $59M | $20M | $16M | $13M | $5M | |
| Accum. Depreciation | $22M | $16M | $10M | $7M | $4M | $2M | $1M | |
| Other Non-current Assets | $9M | $2M | $2M | $3M | $2M | $30.0K | $2M | |
| Total Assets | $1.74B | $978M | $576M | $603M | $606M | $487M | $117M | |
| Accounts Payable | $4M | $6M | $7M | $4M | $4M | $4M | $3M | |
| Accrued Liabilities | $42M | $35M | $34M | $28M | $23M | $10M | $5M | |
| Current Liabilities | $83M | $68M | $86M | $71M | $93M | $111M | $35M | |
| Capital Leases | $67M | $72M | $77M | $12M | $13M | $14M | $17M | |
| Other Non-current Liabilities | · | $0 | $0 | $248.0K | $66.0K | $100.0K | · | |
| Total Liabilities | $163M | $142M | $181M | $113M | $146M | $203M | $82M | |
| Common Stock | $8.0K | $7.0K | $6.0K | $6.0K | $5.0K | $4.0K | · | |
| Retained Earnings | $-1.07B | $-755M | $-531M | $-384M | $-229M | $-129M | $-76M | |
| AOCI | $2M | $-1M | $-552.0K | $-5M | $-660.0K | $-128.0K | $6.0K | |
| Stockholders' Equity | $1.58B | $836M | $395M | $490M | $460M | $284M | $-74M | |
| Liabilities + Equity | $1.74B | $978M | $576M | $603M | $606M | $487M | $117M | |
| Shares Outstanding | 81,323,532 | 64,890,193 | 55,585,305 | 55,039,380 | 51,536,181 | 44,482,186 | 1,929,516 |
现金流 9
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| D&A | $8M | $7M | $4M | $3M | $2M | $2M | $825.0K | |
| Stock-based Comp | $60M | $55M | $43M | $35M | $25M | $5M | $1M | |
| Other Non-cash | $10M | $-33M | $-3M | $-37M | $-56M | $127M | · | |
| Operating Cash Flow | $-233M | $-195M | $-103M | $-153M | $-129M | $88M | $18M | |
| CapEx | $1M | $13M | $34M | $3M | $2M | $9M | $532.0K | |
| Investing Cash Flow | $-521M | $-404M | $140M | $21M | $-100M | $-423M | $-16M | |
| Financing Cash Flow | $991M | $609M | $4M | $153M | $250M | $289M | $35M | |
| Net Change in Cash | $237M | $10M | $41M | $20M | $21M | $-45M | $36M | |
| Free Cash Flow | $-234M | $-207M | $-137M | $-156M | $-131M | $79M | · |
盈利能力 7
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Operating Margin | -891.1% | -555.8% | -210.6% | -344.4% | -138.0% | -136.1% | · | |
| Net Margin | -794.0% | -475.6% | -187.0% | -330.6% | -137.6% | -134.0% | · | |
| Pretax Margin | -794.0% | · | · | · | · | · | · | |
| EBITDA Margin | -869.9% | -540.2% | -206.1% | -338.0% | -134.7% | -130.9% | · | |
| ROA | -22.9% | -28.8% | -24.9% | -25.6% | -18.3% | -15.1% | · | |
| ROE | -24.4% | -25.9% | -37.2% | -30.9% | -21.3% | -15.8% | · | |
| ROIC | -22.1% | · | · | · | · | · | · |
流动性与偿付能力 2
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Current Ratio | 10.5 | 7.5 | 4.7 | 5.9 | 4.9 | 2.7 | · | |
| Quick Ratio | 4.3 | 1.8 | 1.5 | 1.0 | 0.5 | 0.3 | · |
效率 2
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.0 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | · | |
| Receivables Turnover | · | 6.3 | 10.5 | · | · | · | · |
增长率 3
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue YoY | -16.7% | -40.1% | 67.8% | -35.7% | 114.0% | · | · | |
| Revenue CAGR 3Y | -5.7% | -13.5% | 32.2% | · | · | · | · | |
| Revenue CAGR 5Y | 2.9% | · | · | · | · | · | · |
估值 (TTM) 10
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $39M | $47M | $79M | $47M | $73M | $34M | · | |
| Net Income TTM | $-311M | $-224M | $-147M | $-155M | $-100M | $-46M | · | |
| Market Cap | $6.33B | $2.61B | · | $1.37B | $3.27B | $2.76B | · | |
| P/E | -21.1 | -13.5 | -10.1 | -8.7 | -30.4 | -19.7 | · | |
| P/S | 161.4 | 55.5 | · | 29.3 | 44.9 | 81.0 | · | |
| P/B | 4.0 | 3.1 | · | 2.8 | 7.1 | 9.7 | · | |
| P / Tangible Book | 4.0 | 3.1 | · | 2.8 | 7.1 | 9.7 | · | |
| P / Cash Flow | -27.2 | -13.4 | · | -9.0 | -25.4 | 31.3 | · | |
| P / FCF | -27.0 | -12.6 | · | -8.8 | -25.1 | 34.9 | · | |
| Earnings Yield | -4.7% | -7.4% | -9.9% | -11.5% | -3.3% | -5.1% | · |
损益表 14
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $65M | $34M | $3M | $3M | $11M | $22M | $7M | $4M | $26M | $10M | $48M | $5M | $17M | $9M | $16M | $10M | |
| Cost of Revenue | $65M | $34M | $3M | $3M | $11M | $22M | $7M | $4M | $26M | $10M | · | · | · | · | · | · | |
| R&D Expense | $119M | $98M | $84M | $74M | $78M | $80M | $72M | $60M | $59M | $49M | $53M | $48M | $46M | $42M | $43M | $44M | |
| SG&A Expense | $21M | $20M | $17M | $17M | $18M | $16M | $16M | $15M | $17M | $14M | $14M | $14M | $14M | $13M | $12M | $11M | |
| Operating Expenses | $141M | $119M | $101M | $95M | $96M | $97M | $88M | $76M | $77M | $68M | $67M | $62M | $60M | $55M | $55M | $54M | |
| Operating Income | $-76M | $-84M | $-98M | $-93M | $-85M | $-74M | $-81M | $-72M | $-51M | $-58M | $-19M | $-58M | $-43M | $-45M | $-39M | $-45M | |
| Other Non-op | $14M | $15M | $11M | $10M | $8M | $9M | $10M | $10M | $9M | $9M | $5M | $5M | $5M | $4M | $4M | $2M | |
| Income Tax | · | · | · | · | · | · | · | · | · | · | · | $100.0K | $100.0K | $0 | · | $0 | |
| Net Income | $-61M | $-69M | $-87M | $-82M | $-77M | $-66M | $-71M | $-62M | $-42M | $-49M | $-14M | $-53M | $-39M | $-41M | $-35M | $-43M | |
| EPS (Basic) | $-0.62 | $-0.71 | $-0.98 | $-0.94 | $-0.95 | $-0.82 | $-0.89 | $-0.82 | $-0.58 | $-0.69 | $-0.25 | $-0.90 | $-0.67 | $-0.70 | $-0.59 | $-0.79 | |
| EPS (Diluted) | $-0.62 | $-0.71 | $-0.98 | $-0.94 | $-0.95 | $-0.82 | $-0.89 | $-0.82 | $-0.58 | $-0.69 | $-0.25 | $-0.90 | $-0.67 | $-0.70 | $-0.59 | $-0.79 | |
| Shares (Basic) | 98,177,158 | 97,534,269 | -163,405,637 | 87,300,286 | 80,449,405 | 80,146,531 | -144,911,702 | 76,125,975 | 73,059,398 | 70,770,320 | -116,570,361 | 58,421,859 | 58,326,963 | 58,187,038 | -104,025,850 | 54,535,514 | |
| Shares (Diluted) | 98,177,158 | 97,534,269 | -163,405,637 | 87,300,286 | 80,449,405 | 80,146,531 | -144,911,702 | 76,125,975 | 73,059,398 | 70,770,320 | -116,570,361 | 58,421,859 | 58,326,963 | 58,187,038 | -104,025,850 | 54,535,514 | |
| EBITDA | $-76M | $-82M | · | $-93M | $-85M | $-72M | · | $-72M | $-51M | $-56M | · | $-58M | $-43M | $-44M | · | $-45M |
资产负债表 21
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $124M | $144M | $357M | $113M | $336M | $90M | $120M | $111M | $68M | $94M | $110M | $81M | $52M | $50M | $68M | $156M | |
| Receivables | $20M | · | · | · | $40M | · | · | $0 | $0 | $0 | · | · | · | · | · | · | |
| Prepaid Expense | $26M | $27M | $23M | $23M | $23M | $18M | $22M | $17M | $14M | $15M | · | $14M | $14M | $11M | · | $9M | |
| Current Assets | $737M | $677M | $871M | $528M | $728M | $501M | $510M | $569M | $525M | $537M | · | $376M | $385M | $412M | · | $494M | |
| PP&E (Net) | $40M | $42M | $43M | $45M | $49M | $49M | $50M | $51M | $52M | $49M | · | $36M | $27M | $17M | · | $13M | |
| PP&E (Gross) | $66M | $66M | $65M | $67M | $69M | $67M | $67M | $65M | $64M | $60M | · | $46M | $36M | $25M | · | $19M | |
| Accum. Depreciation | $26M | $24M | $22M | $22M | $20M | $18M | $16M | $14M | $12M | $11M | · | $10M | $9M | $8M | · | $6M | |
| Other Non-current Assets | $7M | $8M | $9M | $7M | $5M | $3M | $2M | $0 | $2M | $2M | · | $3M | $3M | $3M | · | $3M | |
| Total Assets | $1.65B | $1.67B | $1.74B | $1.10B | $1.13B | $918M | $978M | $1.03B | $826M | $868M | · | $552M | $582M | $614M | · | $638M | |
| Accounts Payable | $9M | $13M | $4M | $6M | $6M | $10M | $6M | $6M | $7M | $7M | · | $5M | $4M | $6M | · | $6M | |
| Accrued Liabilities | $48M | $35M | $42M | $29M | $28M | $23M | $35M | $27M | $24M | $16M | · | $26M | $22M | $19M | · | $25M | |
| Current Liabilities | $71M | $63M | $83M | $72M | $88M | $59M | $68M | $67M | $62M | $56M | · | $63M | $55M | $62M | · | $91M | |
| Capital Leases | $64M | $66M | $67M | $68M | $70M | $71M | $72M | $74M | $75M | $76M | · | $77M | $71M | $64M | · | $12M | |
| Other Non-current Liabilities | · | · | · | · | · | · | · | · | · | · | · | $8.0K | $230.0K | $237.0K | · | $256.0K | |
| Total Liabilities | $136M | $129M | $163M | $156M | $160M | $132M | $142M | $142M | $141M | $157M | · | $157M | $147M | $152M | · | $126M | |
| Common Stock | $8.0K | $8.0K | $8.0K | $7.0K | $7.0K | $7.0K | $7.0K | $7.0K | $6.0K | $6.0K | · | $6.0K | $6.0K | $6.0K | · | $6.0K | |
| Retained Earnings | $-1.20B | $-1.14B | $-1.07B | $-979M | $-897M | $-820M | $-755M | $-684M | $-621M | $-579M | · | $-516M | $-464M | $-425M | · | $-349M | |
| AOCI | $-7M | $-4M | $2M | $2M | $279.0K | $-58.0K | $-1M | $2M | $-2M | $-2M | · | $-2M | $-4M | $-3M | · | $-6M | |
| Stockholders' Equity | $1.51B | $1.54B | $1.58B | $946M | $971M | $786M | $836M | $893M | $685M | $711M | $395M | $396M | $435M | $462M | $490M | $513M | |
| Liabilities + Equity | $1.65B | $1.67B | $1.74B | $1.10B | $1.13B | $918M | $978M | $1.03B | $826M | $868M | · | $552M | $582M | $614M | · | $638M | |
| Shares Outstanding | 82,788,253 | 82,182,101 | 81,323,532 | 71,741,174 | 70,557,442 | 65,112,714 | 64,890,193 | 64,748,226 | 61,572,383 | 61,353,146 | · | 55,450,239 | 55,390,259 | 55,276,226 | · | 54,751,429 |
现金流 9
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $1M | $891.0K | $895.0K | $900.0K | $879.0K | $818.0K | $767.0K | |
| Stock-based Comp | $19M | $16M | $14M | $16M | $15M | $14M | $14M | $15M | $14M | $12M | $11M | $12M | $11M | $9M | $9M | $9M | |
| Other Non-cash | · | $-38M | · | · | · | $-30M | · | · | · | $-4M | · | · | · | $-13M | · | · | |
| Operating Cash Flow | $-54M | $-89M | $-67M | $-27M | $-60M | $-79M | $-62M | $-50M | $-43M | $-40M | $8M | $-32M | $-35M | $-44M | $-40M | $-34M | |
| CapEx | $473.0K | $434.0K | $106.0K | $181.0K | $695.0K | $467.0K | $936.0K | $-189.0K | $5M | $7M | $12M | $8M | $11M | $4M | $373.0K | $1M | |
| Investing Cash Flow | $20M | $-143M | $-394M | $-235M | $60M | $49M | $69M | $-158M | $16M | $-331M | $19M | $61M | $36M | $25M | $-50M | $-37M | |
| Financing Cash Flow | $14M | $19M | $705M | $40M | $246M | $258.0K | $3M | $251M | $1M | $354M | $2M | $-206.0K | $1M | $1M | $2M | $150M | |
| Net Change in Cash | $-20M | $-213M | $244M | $-223M | $246M | $-30M | $10M | $43M | $-26M | $-16M | $29M | $29M | $2M | $-18M | $-87M | $79M | |
| Free Cash Flow | · | $-89M | · | · | · | $-80M | · | · | · | $-47M | · | · | · | $-48M | · | · |
盈利能力 5
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -116.3% | -244.9% | · | -3347.4% | -736.8% | -336.8% | · | -1927.9% | -198.5% | -562.2% | · | -1216.4% | -262.7% | -478.8% | · | -469.9% | |
| Net Margin | -94.2% | -201.5% | · | -2973.0% | -667.6% | -296.8% | · | -1670.3% | -164.0% | -472.0% | · | -1118.2% | -235.0% | -432.4% | · | -450.2% | |
| EBITDA Margin | -116.3% | -239.0% | · | -3347.4% | -736.8% | -327.5% | · | -1927.9% | -198.5% | -548.0% | · | -1216.4% | -262.7% | -469.5% | · | -469.9% | |
| ROA | -4.4% | -5.3% | · | -7.7% | -7.8% | -7.3% | · | -7.9% | -6.0% | -6.6% | · | -8.9% | -7.0% | -7.0% | · | -6.7% | |
| ROE | -4.9% | -5.9% | · | -8.9% | -9.2% | -8.8% | · | -9.7% | -7.5% | -8.3% | · | -11.6% | -9.3% | -9.2% | · | -8.6% |
流动性与偿付能力 2
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 10.3 | 10.8 | · | 7.4 | 8.3 | 8.5 | · | 8.5 | 8.5 | 9.6 | · | 5.9 | 7.1 | 6.6 | · | 5.4 | |
| Quick Ratio | 2.0 | 2.3 | · | 1.6 | 4.3 | 1.5 | · | 1.7 | 1.1 | 1.7 | · | 1.3 | 1.0 | 0.8 | · | 1.7 |
效率 2
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | |
| Receivables Turnover | 2.2 | · | · | · | 0.6 | · | · | · | · | · | · | · | · | · | · | · |
估值 (TTM) 10
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $114M | $71M | · | $40M | $63M | $62M | · | $44M | $57M | $41M | · | $40M | $47M | $40M | · | $51M | |
| Net Income TTM | $-289M | $-294M | · | $-287M | $-247M | $-219M | · | $-206M | $-182M | $-181M | · | $-176M | $-163M | $-161M | · | $-149M | |
| Market Cap | $9.49B | $6.84B | · | $4.06B | $3.08B | $1.78B | · | $3.06B | $1.84B | $2.47B | · | $771M | $1.27B | $1.64B | · | $1.19B | |
| P/E | -35.6 | -24.4 | · | -16.0 | -13.8 | -9.4 | · | -15.8 | -10.5 | -13.6 | · | -4.5 | -7.8 | -9.9 | · | -7.7 | |
| P/S | 83.6 | 96.8 | · | 101.3 | 48.9 | 28.8 | · | 69.0 | 32.1 | 60.2 | · | 19.1 | 27.1 | 40.8 | · | 23.4 | |
| P/B | 6.3 | 4.4 | · | 4.3 | 3.2 | 2.3 | · | 3.4 | 2.7 | 3.5 | · | 1.9 | 2.9 | 3.5 | · | 2.3 | |
| P / Tangible Book | 6.3 | 4.4 | · | 4.3 | 3.2 | 2.3 | · | 3.4 | 2.7 | 3.5 | · | 1.9 | 2.9 | 3.5 | · | 2.3 | |
| P / Cash Flow | · | -77.0 | · | · | · | -22.5 | · | · | · | -62.3 | · | · | · | -37.3 | · | · | |
| P / FCF | · | -76.7 | · | · | · | -22.4 | · | · | · | -52.5 | · | · | · | -34.1 | · | · | |
| Earnings Yield | -2.8% | -4.1% | · | -6.2% | -7.3% | -10.6% | · | -6.3% | -9.5% | -7.4% | · | -22.0% | -12.8% | -10.1% | · | -13.1% |
财务报表 损益表、资产负债表、现金流量表 — 年度，近5年
损益表
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| 收入 | $39M | $47M | $79M | $47M | $73M |
| 营业利润率 % | -891.1% | -555.8% | -210.6% | -344.4% | -138.0% |
| 净收入 | $-311M | $-224M | $-147M | $-155M | $-100M |
| 稀释后每股收益 (EPS) | $-3.69 | $-2.98 | $-2.52 | $-2.87 | $-2.09 |
资产负债表
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| 流动比率 | 10.5 | 7.5 | 4.7 | 5.9 | 4.9 |
| 速动比率 | 4.3 | 1.8 | 1.5 | 1.0 | 0.5 |
现金流
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| 自由现金流 | $-234M | $-207M | $-137M | $-156M | $-131M |
我的指标 您的个人关注列表 — 来自完整基本面的选定行
📊
选择对您重要的指标 — 点击上方完整基本面中任意行的 ➕。
您的选择已保存，并会跟随您浏览所有股票。
机构持有人 (13F) 305 家申报者 · $8.0B 总计 · 截至 2026年6月30日
在其季度SEC表格13F中报告持有此股票的机构。仅限多头头寸；单个申报人可能因单独的期权腿而出现两次。 大的抵消性看跌/看涨腿通常反映做市或对冲库存，而非方向性判断。
机构活动 — Q2 2026 与上一季度对比
| 新仓位 | 已退出持仓 | 增加 | 减少 | 净股数变动 |
|---|---|---|---|---|
| 52 (+6 与上一季度对比) | 23 (-13 与上一季度对比) | 99 (+6 与上一季度对比) | 78 (+5 与上一季度对比) | +5.6M |
与Q1 2026对比。 SEC 13F表格的提交截止日期是季度末后45天，外加少量延迟提交的缓冲期——在此窗口期内的季度将被跳过，优先显示最近一个已完整报告的季度对。
| 机构 | 价值 | 股份 | % 已追踪的13F | 类型 |
|---|---|---|---|---|
| BAKER BROS. ADVISORS LP | $992725940 | 8657242 | 12.48% | 股份 |
| FMR LLC | $985896654 | 8597686 | 12.40% | 股份 |
| Avoro Capital Advisors LLC | $857129238 | 7474747 | 10.78% | 股份 |
| BVF INC/IL | $444008203 | 3872052 | 5.58% | 股份 |
| WELLINGTON MANAGEMENT GROUP LLP | $376085378 | 3279719 | 4.73% | 股份 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $343114771 | 2992193 | 4.31% | 股份 |
| Siren, L.L.C. | $336651626 | 2935830 | 4.23% | 股份 |
| VANGUARD CAPITAL MANAGEMENT LLC | $336255785 | 2932378 | 4.23% | 股份 |
| Atlas Venture Life Science Advisors, LLC | $326527526 | 2847541 | 4.11% | 股份 |
| STATE STREET CORP | $313877705 | 2737226 | 3.95% | 股份 |
| GEODE CAPITAL MANAGEMENT, LLC | $181558708 | 1582987 | 2.28% | 股份 |
| Capital Research Global Investors | $159262984 | 1388881 | 2.00% | 股份 |
| Driehaus Capital Management LLC | $105408448 | 919233 | 1.33% | 股份 |
| GOLDMAN SACHS GROUP INC | $101597391 | 885998 | 1.28% | 股份 |
| Merck & Co., Inc. | $88544161 | 772165 | 1.11% | 股份 |
| NORGES BANK | $86833399 | 757246 | 1.09% | 股份 |
| FEDERATED HERMES, INC. | $85933469 | 749398 | 1.08% | 股份 |
| FRONTIER CAPITAL MANAGEMENT CO LLC | $84955104 | 740866 | 1.07% | 股份 |
| ALLIANCEBERNSTEIN L.P. | $81750884 | 981521 | 1.03% | 股份 |
| DIMENSIONAL FUND ADVISORS LP | $77152155 | 672819 | 0.97% | 股份 |
| Holocene Advisors, LP | $72996514 | 636579 | 0.92% | 股份 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $60744024 | 529729 | 0.76% | 股份 |
| EVENTIDE ASSET MANAGEMENT, LLC | $57811287 | 504210 | 0.73% | 股份 |
| JENNISON ASSOCIATES LLC | $57676487 | 502978 | 0.73% | 股份 |
| Woodline Partners LP | $57434534 | 500868 | 0.72% | 股份 |
| Rock Springs Capital Management LP | $51963399 | 453156 | 0.65% | 股份 |
| VANGUARD FIDUCIARY TRUST CO | $51570654 | 449731 | 0.65% | 股份 |
| Boxer Capital Management, LLC | $49204897 | 429100 | 0.62% | 股份 |
| Pictet Asset Management Holding SA | $44984008 | 395540 | 0.57% | 股份 |
| BRAIDWELL LP | $43363951 | 378163 | 0.55% | 股份 |
| BNP PARIBAS FINANCIAL MARKETS | $43100784 | 375868 | 0.54% | 股份 |
| TWO SIGMA INVESTMENTS, LP | $42585457 | 371374 | 0.54% | 股份 |
| Clearbridge Investments, LLC | $39815871 | 347221 | 0.50% | 股份 |
| Octagon Capital Advisors LP | $35547700 | 310000 | 0.45% | 股份 |
| Nextech Invest Ltd. | $31981004 | 278896 | 0.40% | 股份 |
| Alyeska Investment Group, L.P. | $31701095 | 276455 | 0.40% | 股份 |
| TD Asset Management Inc | $31293443 | 272900 | 0.39% | 股份 |
| TWO SIGMA ADVISERS, LP | $29085378 | 373800 | 0.37% | 股份 |
| Commodore Capital LP | $28667500 | 250000 | 0.36% | 股份 |
| RTW INVESTMENTS, LP | $27520800 | 240000 | 0.35% | 股份 |
| GILDER GAGNON HOWE & CO LLC | $26265508 | 229053 | 0.33% | 股份 |
| Polar Capital Holdings Plc | $23363668 | 203747 | 0.29% | 股份 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | $22934000 | 200000 | 0.29% | 股份 |
| Candriam S.C.A. | $22096270 | 192880 | 0.28% | 股份 |
| BANK OF AMERICA CORP /DE/ | $21627335 | 188605 | 0.27% | 股份 |
| Eagle Health Investments LP | $19052191 | 166148 | 0.24% | 股份 |
| Connor, Clark & Lunn Investment Management Ltd. | $17189950 | 149908 | 0.22% | 股份 |
| DIADEMA PARTNERS LP | $17166099 | 149700 | 0.22% | 买入期权 |
| Foresite Capital Management VI LLC | $16779890 | 146332 | 0.21% | 股份 |
| WCM INVESTMENT MANAGEMENT, LLC | $16595869 | 151810 | 0.21% | 股份 |
| JANE STREET GROUP, LLC | $15732724 | 137200 | 0.20% | 买入期权 |
| Deer Management Co. LLC | $14436380 | 125895 | 0.18% | 股份 |
| TimesSquare Capital Management, LLC | $14063183 | 168846 | 0.18% | 股份 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $13794801 | 120300 | 0.17% | 买入期权 |
| Caption Management, LLC | $13760400 | 120000 | 0.17% | 卖出期权 |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | $13703409 | 119503 | 0.17% | 股份 |
| BOONE CAPITAL MANAGEMENT LLC | $12977548 | 113173 | 0.16% | 股份 |
| ARMISTICE CAPITAL, LLC | $12186210 | 106272 | 0.15% | 股份 |
| First Turn Management, LLC | $11757459 | 102533 | 0.15% | 股份 |
| Ensign Peak Advisors, Inc | $11198672 | 97660 | 0.14% | 股份 |
| Squarepoint Ops LLC | $11144663 | 97189 | 0.14% | 股份 |
| Swiss National Bank | $10331767 | 90100 | 0.13% | 股份 |
| Universal- Beteiligungs- und Servicegesellschaft mbH | $10262276 | 89494 | 0.13% | 股份 |
| Bank of New York Mellon Corp | $9823664 | 85669 | 0.12% | 股份 |
| RHUMBLINE ADVISERS | $9252017 | 80684 | 0.12% | 股份 |
| JPMORGAN CHASE & CO | $9149756 | 81205 | 0.12% | 股份 |
| Burkehill Global Management, LP | $8600250 | 75000 | 0.11% | 股份 |
| VICTORY CAPITAL MANAGEMENT INC | $8524567 | 74340 | 0.11% | 股份 |
| CITIGROUP INC | $8504959 | 74169 | 0.11% | 股份 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $8462646 | 73800 | 0.11% | 卖出期权 |
| CITADEL ADVISORS LLC | $8328253 | 72628 | 0.10% | 股份 |
| FIFTH THIRD BANCORP | $7529104 | 65659 | 0.09% | 股份 |
| BlackRock, Inc. | $7486231 | 65285 | 0.09% | 股份 |
| Yiheng Capital Management, L.P. | $7274665 | 63440 | 0.09% | 股份 |
| XTX Topco Ltd | $7052320 | 61501 | 0.09% | 股份 |
| FIRST TRUST ADVISORS LP | $7037068 | 61368 | 0.09% | 股份 |
| Atika Capital Management LLC | $6957488 | 60674 | 0.09% | 股份 |
| Nicholas Investment Partners, LP | $6257427 | 54569 | 0.08% | 股份 |
| Ikarian Capital, LLC | $5779368 | 50400 | 0.07% | 卖出期权 |
| Patient Square Capital LP | $5446825 | 47500 | 0.07% | 股份 |
| VANGUARD ASSET MANAGEMENT, Ltd | $5250281 | 45786 | 0.07% | 股份 |
| PEREGRINE CAPITAL MANAGEMENT LLC | $5237094 | 45671 | 0.07% | 股份 |
| CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | $4687728 | 56282 | 0.06% | 股份 |
| UBS Group AG | $4678880 | 40803 | 0.06% | 股份 |
| AXA Investment Managers S.A. | $4558224 | 80534 | 0.06% | 股份 |
| VOYA INVESTMENT MANAGEMENT LLC | $4451260 | 38818 | 0.06% | 股份 |
| MARSHALL WACE, LLP | $4273177 | 37265 | 0.05% | 股份 |
| STATE OF WISCONSIN INVESTMENT BOARD | $4223640 | 36833 | 0.05% | 股份 |
| MetLife Investment Management, LLC | $4184767 | 36494 | 0.05% | 股份 |
| Rafferty Asset Management, LLC | $4046360 | 35287 | 0.05% | 股份 |
| Odyssean, LLC | $3954395 | 34485 | 0.05% | 股份 |
| Zurcher Kantonalbank (Zurich Cantonalbank) | $3851880 | 33591 | 0.05% | 股份 |
| CITADEL ADVISORS LLC | $3841445 | 33500 | 0.05% | 卖出期权 |
| Aquilo Capital Management, LLC | $3791320 | 138521 | 0.05% | 股份 |
| Nan Fung Group Holdings Ltd | $3540436 | 30875 | 0.04% | 股份 |
| Moody Aldrich Partners LLC | $3440788 | 30006 | 0.04% | 股份 |
| SEVEN GRAND MANAGERS, LLC | $3440100 | 30000 | 0.04% | 股份 |
| 683 Capital Management, LLC | $3440100 | 30000 | 0.04% | 卖出期权 |
| CITADEL ADVISORS LLC | $3428633 | 29900 | 0.04% | 买入期权 |
| NEW YORK STATE COMMON RETIREMENT FUND | $3300203 | 28780 | 0.04% | 股份 |
公司内部人士 24 位内幕人士 · 10 位高管 · 13 位董事
| 内部人士 | 角色 | 上次活动 | 持股数量 | 买入 12个月 | 卖出 12个月 | 净额 12个月 |
|---|---|---|---|---|---|---|
| Nello Mainolfi | Chief Executive Officer | 2026年7月7日 M | 666568 | 0 | 21 | $-34875625 |
| Bruce N. Jacobs | Chief Financial Officer | 2026年6月30日 M | 244883 | 0 | 16 | $-13917105 |
| Jeremy G Chadwick | Chief Operating Officer | 2026年5月27日 S | 44018 | 0 | 29 | $-15599618 |
| Terence Rooney | Chief Medical Officer | 2026年7月27日 A | 38000 | 0 | 0 | $0 |
| Noah Goodman | Chief Business Officer | 2026年7月1日 S | 47179 | 0 | 9 | $-2223845 |
| Jared Gollob | Chief Medical Officer | 2026年3月2日 A | 117134 | 0 | 18 | $-9134491 |
| Brian Adams | Chief Legal Officer | 2026年3月2日 A | 56625 | 0 | 0 | $0 |
| Ellen Chiniara | Chief Legal Officer | 2025年3月3日 A | 80085 | 0 | 0 | $0 |
| Elaine Caughey | Chief Business Officer | 2023年3月1日 A | 18986 | 0 | 0 | $0 |
| Richard Chesworth | Chief Scientific Officer | 2021年8月27日 M | 0 | 0 | 0 | $0 |
| Bruce Booth | 董事 | 2026年6月29日 S | 462856 | 0 | 137 | $-195559433 |
| Hrustanovic Gorjan | 董事 | 2026年6月24日 A | — | 0 | 0 | $0 |
| Elena Ridloff | 董事 | 2026年6月24日 A | 0 | 0 | 4 | $-1285644 |
| Pamela Esposito | 董事 | 2026年6月24日 A | 1000 | 0 | 12 | $-3054174 |
| Jeffrey W. Albers | 董事 | 2026年6月24日 A | 0 | 0 | 3 | $-744757 |
| Victor Sandor | 董事 | 2026年6月24日 A | — | 0 | 0 | $0 |
| John Maraganore | 董事 | 2026年6月24日 A | — | 0 | 0 | $0 |
| Leigh Morgan | 董事 | 2024年6月18日 A | — | 0 | 0 | $0 |
| Joanna Horobin | 董事 | 2024年6月7日 M | 0 | 0 | 0 | $0 |
| Donald William Nicholson | 董事 | 2022年6月15日 A | — | 0 | 0 | $0 |
| Steven Edward Hall | 董事 | 2020年8月25日 C | 2192249 | 0 | 0 | $0 |
| Andrew Hedin | 董事 | 2020年8月20日 A | — | 0 | 0 | $0 |
| Atlas Venture Fund X, L.P. | 10% 所有者 | 2021年5月18日 J | 5763012 | 0 | 0 | $0 |
| Wellington Biomedical Innovation Master Investors (Cayman) I L.P. | 10% 所有者 | 2020年8月25日 C | 959211 | 0 | 0 | $0 |
来自SEC表格3/4/5申报的内部人士；净额=仅公开市场买卖
激进投资者及 5%+ 股东 4 持仓
提交了 SEC Schedule 13D 的投资者 — 持有超过 5% 的受益所有权，意图影响发行人（激进股东持股、董事会活动、并购）。每一行显示该申报人持仓的最新已知状态。
| 申报人 | 已申报 | 持股 | 状态 | 目的 | 申报 |
|---|---|---|---|---|---|
| BIOTECHNOLOGY VALUE FUND L P, BVF I GP LLC, BIOTECHNOLOGY VALUE FUND II LP, BVF II GP LLC, Biotechnology Value Trading Fund OS LP, BVF Partners OS Ltd., BVF GP HOLDINGS LLC, BVF PARTNERS L P/IL, BVF INC/IL, LAMPERT MARK N, Hrustanovic Gorjan ×2 申报 | 2026年6月26日 | 6.30% | 修订 | — | SEC |
| Baker Bros. Advisors LP, Baker Bros. Advisors (GP) LLC, Julian C. Baker, Felix J. Baker ×4 申报 | 2025年12月11日 | 10.90% | 修订 | 资本结构 | SEC |
| BIOTECHNOLOGY VALUE FUND, L.P., BVF I GP LLC, BIOTECHNOLOGY VALUE FUND II, L.P., BVF II GP LLC, BIOTECHNOLOGY VALUE TRADING FUND OS, L.P., BVF PARTNERS OS LTD., BVF GP HOLDINGS LLC, BVF PARTNERS L.P., BVF INC., MARK N. LAMPERT, GORJAN HRUSTANOVIC ×5 申报 | 2024年1月9日 | — | 初始申报 | — | SEC |
| Vertex Pharmaceuticals Incorporated ×2 申报 | 2023年6月5日 | — | 初始申报 | — | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
ETF持仓 由 64 只交易所交易基金持有
权重仅反映直接股权持仓（N-PORT）；杠杆基金或基于衍生品的基金可能持有未显示的额外掉期敞口。
| 基金 | 权重 | 单位 | 截至 | 来源 |
|---|---|---|---|---|
| SBIO · ALPS ETF Trust | 4.23% | 84154 NS | 2026年5月31日 | N-PORT |
| FMED · Fidelity Covington Trust | 1.99% | 10000 NS | 2026年5月31日 | N-PORT |
| HAPS · Harbor ETF Trust | 1.76% | 34157 NS | 2026年4月30日 | N-PORT |
| GURU · Global X Funds | 1.04% | 7506 NS | 2026年4月30日 | N-PORT |
| LABU · Direxion Shares ETF Trust | 0.93% | 59553 NS | 2026年4月30日 | N-PORT |
| BBC · ETFis Series Trust I | 0.67% | 3077 NS | 2026年4月30日 | N-PORT |
| IBBQ · Invesco Exchange-Traded Fund Trus... | 0.66% | 4553 SH | 2026年8月19日 | 每日 |
| IBB · iShares Trust | 0.63% | 528006 SH | 2026年8月19日 | 每日 |
| MMSC · First Trust Exchange-Traded Fund ... | 0.50% | 3204 NS | 2026年5月31日 | N-PORT |
| FNY · First Trust Exchange-Traded Alpha... | 0.39% | 24697 NS | 2026年4月30日 | N-PORT |
| IWO · iShares Trust | 0.38% | 470873 SH | 2026年8月19日 | 每日 |
| VTWG · VANGUARD SCOTTSDALE FUNDS | 0.35% | 55351 SH | 2026年8月19日 | 每日 |
| BIB · ProShares Trust | 0.33% | 3017 NS | 2026年5月31日 | N-PORT |
| TMFX · RBB Fund, Inc. | 0.33% | 1305 NS | 2026年5月31日 | N-PORT |
| ESSC · Strategy Shares | 0.31% | 979 NS | 2026年4月30日 | N-PORT |
| IWM · iShares Trust | 0.24% | 1601097 SH | 2026年8月19日 | 每日 |
| BBSC · J.P. Morgan Exchange-Traded Fund ... | 0.23% | 20749 NS | 2026年4月30日 | N-PORT |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0.22% | 360394 SH | 2026年8月19日 | 每日 |
| VBK · VANGUARD INDEX FUNDS | 0.21% | 871540 SH | 2026年8月19日 | 每日 |
| BKSE · BNY Mellon ETF Trust | 0.19% | 1938 NS | 2026年4月30日 | N-PORT |
| VFMO · VANGUARD WELLINGTON FUND | 0.19% | 32324 SH | 2026年8月19日 | 每日 |
| RSSL · Global X Funds | 0.14% | 24820 NS | 2026年4月30日 | N-PORT |
| FNX · First Trust Exchange-Traded Alpha... | 0.13% | 21796 NS | 2026年4月30日 | N-PORT |
| ITWO · ProShares Trust | 0.12% | 2699 NS | 2026年5月31日 | N-PORT |
| FAD · First Trust Exchange-Traded Alpha... | 0.11% | 6792 NS | 2026年4月30日 | N-PORT |
| SCHA · SCHWAB STRATEGIC TRUST | 0.11% | 294706 NS | 2026年5月31日 | N-PORT |
| ISCV · iShares Trust | 0.10% | 5956 SH | 2026年8月19日 | 每日 |
| ISCB · iShares Trust | 0.10% | 2398 SH | 2026年8月19日 | 每日 |
| ISCG · iShares Trust | 0.10% | 8334 SH | 2026年8月19日 | 每日 |
| PRFZ · Invesco Exchange-Traded Fund Trust | 0.09% | 22388 SH | 2026年8月19日 | 每日 |
| VB · VANGUARD INDEX FUNDS | 0.09% | 1509269 SH | 2026年8月19日 | 每日 |
| ESML · iShares Trust | 0.09% | 21157 SH | 2026年8月19日 | 每日 |
| IWN · iShares Trust | 0.08% | 102126 SH | 2026年8月19日 | 每日 |
| DFAS · Dimensional ETF Trust | 0.08% | 143695 NS | 2026年4月30日 | N-PORT |
| VXF · VANGUARD INDEX FUNDS | 0.08% | 726357 SH | 2026年8月19日 | 每日 |
| VTWV · VANGUARD SCOTTSDALE FUNDS | 0.08% | 9461 SH | 2026年8月19日 | 每日 |
| VHT · VANGUARD WORLD FUND | 0.08% | 134854 SH | 2026年8月19日 | 每日 |
| UWM · ProShares Trust | 0.07% | 2111 NS | 2026年5月31日 | N-PORT |
| FHLC · FIDELITY COVINGTON TRUST | 0.06% | 21910 NS | 2026年4月30日 | N-PORT |
| WSML · iShares Trust | 0.05% | 2882 SH | 2026年8月19日 | 每日 |
| URTY · ProShares Trust | 0.05% | 2136 NS | 2026年5月31日 | N-PORT |
| AVIE · AMERICAN CENTURY ETF TRUST | 0.05% | 61 NS | 2026年5月31日 | N-PORT |
| GSSC · Goldman Sachs ETF Trust | 0.04% | 5327 NS | 2026年5月31日 | N-PORT |
| AVMC · AMERICAN CENTURY ETF TRUST | 0.03% | 1604 NS | 2026年5月31日 | N-PORT |
| MSSM · MORGAN STANLEY PATHWAY FUNDS | 0.02% | 2239 NS | 2026年5月31日 | N-PORT |
| HDG · ProShares Trust | 0.02% | 54 NS | 2026年5月31日 | N-PORT |
| DFAC · Dimensional ETF Trust | 0.02% | 93115 NS | 2026年4月30日 | N-PORT |
| ONEQ · Fidelity Commonwealth Trust | 0.01% | 19514 NS | 2026年5月31日 | N-PORT |
| DXUV · Dimensional ETF Trust | 0.01% | 675 NS | 2026年4月30日 | N-PORT |
| TILT · FlexShares Trust | 0.01% | 2916 NS | 2026年4月30日 | N-PORT |